Clinical Trial Update: An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease [EARLY_Phase 1]

View source ↗

Summary

An early-phase exploratory study to assess the safety and efficacy of a CD19/BCMA CAR-NK cell therapy for relapsed and refractory IgG4-related disease, with rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• CD19/BCMA CAR-NK

Snippet

Sponsor: Changhai Hospital | Conditions: IgG4 Related Disease | EARLY_Phase 1 | Status: NOT_YET_RECRUITING